Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIA Open-Label, to Evaluate the Safety, Tolerability, and Efficacy Trend of SCI -110 in Patients With AD and Agitation

NCT05239390 is registered in ClinicalTrials.gov with The Israeli Medical Center for Alzheimer's as lead sponsor.

NCT NCT05239390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05239390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIA Open-Label, to Evaluate the Safety, Tolerability, and Efficacy Trend of SCI -110 in Patients With AD and Agitation
Lead sponsor
The Israeli Medical Center for Alzheimer's
Phase
Phase 2
Overall status
Unknown status
Start date
December 29, 2021
Completion date
June 29, 2023
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease